HMGN (Hemagen Diagnostics) EBIT per Share: $-0.03 (TTM As of Sep. 2012)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Hemagen Diagnostics EBIT per Share?

Hemagen Diagnostics HMGN EBIT per Share is $-0.03 as of Sep. 2012.

Hemagen Diagnostics's EBIT per Share for the three months ended in Sep. 2012 was $-0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2012 was $-0.03.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Hemagen Diagnostics's EBIT per Share or its related term are showing as below:

HMGN's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.4
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Hemagen Diagnostics's EBIT for the three months ended in Sep. 2012 was $-0.04 Mil.

Hemagen Diagnostics  (OTCPK:HMGN) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Hemagen Diagnostics EBIT per Share Related Terms

Hemagen Diagnostics EBIT per Share Historical Data

* Premium members only.

The historical data trend for Hemagen Diagnostics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemagen Diagnostics EBIT per Share Chart

Hemagen Diagnostics Annual Data
Trend Sep03 Sep04 Sep05 Sep06 Sep07 Sep08 Sep09 Sep10 Sep11 Sep12
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 -0.02 0.02 -0.03 -0.03

Hemagen Diagnostics Quarterly Data
Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.02 -0.01 -0.00 -0.00

Hemagen Diagnostics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Hemagen Diagnostics's EBIT per Share for the fiscal year that ended in Sep. 2012 is calculated as

EBIT per Share(A: Sep. 2012 )
=EBIT/Shares Outstanding (Diluted Average)
=-0.438/15.496
=-0.03

Hemagen Diagnostics's EBIT per Share for the quarter that ended in Sep. 2012 is calculated as

EBIT per Share(Q: Sep. 2012 )
=EBIT/Shares Outstanding (Diluted Average)
=-0.043/15.500
=-0.00

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2012 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of $-0.03 mean?
Hemagen Diagnostics (HMGN) has a EBIT per Share of $-0.03 as of Sep. 2012. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Hemagen Diagnostics and its competitors.
Is Hemagen Diagnostics' EBIT per Share too high?
Hemagen Diagnostics' current EBIT per Share is $-0.03.
How does Hemagen Diagnostics' EBIT per Share compare to OBMP and NSPX?
Hemagen Diagnostics' EBIT per Share of $-0.03 can be compared against companies in the Biotechnology industry. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,171 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Hemagen Diagnostics and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hemagen Diagnostics's current EBIT per Share is $-0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemagen Diagnostics stock overvalued right now?
Hemagen Diagnostics (HMGN) has a current EBIT per Share of $-0.03. The current EBIT per Share is $-0.03. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Hemagen Diagnostics (HMGN), the current EBIT per Share is $-0.03 as of Sep. 2012. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hemagen Diagnostics Business Description

Address 9033 Red Branch Road, Columbia, MD, USA, 21045
Hemagen Diagnostics Inc is a biotechnology company. It develops, manufactures and markets Food and Drug Administration cleared proprietary medical diagnostic test kits and components. The company's Virgo line of Immunoassays are used to aid in the diagnosis of autoimmune and infectious diseases and acute-phase proteins. The assays utilize multiple technologies including ELISA, immunofluorescence (IFA) and hemagglutination (HA). Its products include ANA Screen ELISA 96 Test System, Rubella IgG ELISA 96 Test System, AMA IFA 48 Test System and others.